Cancer Immunotherapy Market by Product Type (Monoclonal Antibodies, Checkpoint Inhibitors, Cytokine Therapies, Vaccines, CAR-T Cell Therapies), by Service Type (Preclinical Discovery, Clinical Trial Services, Discovery Services, Regulatory Consulting), by Therapeutic Area (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer), by End-User Industry (Biopharmaceutical Companies, Research & Development Institutes, Academic & Research Institutions, Contract Research Organizations (CROs)); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cancer Immunotherapy Market was valued at USD 154.5 billion in 2023 and will surpass USD 338.3 billion by 2030; growing at a CAGR of 11.9% during 2024 - 2030. The global cancer immunotherapy market has experienced rapid expansion, driven by groundbreaking advancements in the development of therapies that utilize the body's immune system to fight cancer. Cancer immunotherapy, which includes a range of treatment approaches such as checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, has transformed the oncology landscape. The growth in this market is further fueled by the increasing prevalence of cancer worldwide, along with ongoing research and the rapid approval of new treatments. As the demand for more effective and personalized cancer treatments rises, the cancer immunotherapy market is poised for sustained growth over the next decade. Monoclonal Antibodies Segment Is Largest Owing to Widespread Use and Efficacy Monoclonal antibodies (mAbs) remain the largest subsegment in the cancer immunotherapy market, accounting for a significant portion of the market share. These antibodies are engineered to target specific antigens found on cancer cells, leading to improved treatment outcomes. The success of therapies like Herceptin (trastuzumab) for breast cancer and Rituxan (rituximab) for lymphoma has established mAbs as a cornerstone in cancer treatment. Their high specificity and ability to trigger immune responses make them highly effective, thereby contributing to their dominance in the market. Additionally, mAbs are increasingly used in combination therapies, which further enhances their clinical efficacy. The expanding pipeline of mAbs targeting different types of cancer, including prostate, breast, and colorectal cancers, continues to drive the market forward. As more cancer types are being addressed with these therapies, the demand for monoclonal antibodies will likely continue to increase, solidifying their position as the largest segment in cancer immunotherapy. Preclinical Discovery Services Are Fastest Growing Due to Increased Research Investment Preclinical discovery services have emerged as the fastest-growing segment in the cancer immunotherapy market. As the pharmaceutical and biotechnology industries invest more in the early stages of drug development, the demand for preclinical testing and discovery services is rising. These services play a crucial role in identifying potential drug candidates, optimizing their efficacy, and ensuring their safety before clinical trials. With the growing focus on personalized cancer treatments, more targeted therapies are being developed, increasing the need for specialized preclinical discovery services. Moreover, advancements in genomics, proteomics, and other molecular techniques have enhanced the ability of researchers to identify and validate new drug targets. This trend has led to a surge in preclinical discoveries, making it one of the fastest-growing service areas within the cancer immunotherapy market. The growth in this segment reflects the overall increase in research and development activities, especially in the field of immuno-oncology. Lung Cancer Segment Is Largest Due to High Prevalence and Treatment Demand The lung cancer segment remains the largest therapeutic area in the cancer immunotherapy market, primarily driven by the high incidence and mortality rates associated with this disease. Lung cancer is one of the most common and deadly cancers globally, which has resulted in substantial demand for innovative treatment options. Immunotherapies, particularly checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have revolutionized lung cancer treatment by offering significant survival benefits for patients with advanced-stage disease. The increasing availability of targeted immunotherapies for lung cancer is accelerating the growth of this therapeutic area. Furthermore, the combination of checkpoint inhibitors with other therapies, such as chemotherapy and targeted therapies, is yielding promising results in improving outcomes for lung cancer patients, ensuring that this segment remains the largest and most significant in the cancer immunotherapy market. Biopharmaceutical Companies Are Leading End-User Industry Players Biopharmaceutical companies are the largest end-user industry in the cancer immunotherapy market, given their pivotal role in the development and commercialization of immuno-oncology drugs. These companies are at the forefront of research and development efforts, driving innovation in cancer treatment. With their extensive resources, biopharmaceutical companies fund clinical trials, engage in strategic partnerships, and leverage cutting-edge technologies to advance new therapies from the laboratory to the market. The presence of major pharmaceutical giants like Merck, Bristol Myers Squibb, and Roche has further cemented the dominance of biopharmaceutical companies in this segment. These companies not only manufacture and distribute cancer immunotherapies but also invest heavily in post-market surveillance, ensuring the safety and efficacy of their treatments across diverse patient populations. Their contributions are critical in meeting the growing demand for cancer immunotherapies and ensuring that new treatments reach the global market. North America Remains the Largest Region Due to Strong Healthcare Infrastructure North America is the largest regional market for cancer immunotherapy, accounting for a significant share of the global market. The region's dominance is attributed to its robust healthcare infrastructure, high levels of research and development, and the presence of key pharmaceutical companies. The U.S., in particular, has been a leader in the approval and adoption of novel cancer therapies, with several immuno-oncology drugs receiving accelerated approvals from the U.S. Food and Drug Administration (FDA). In addition, the growing number of clinical trials, along with favorable reimbursement policies and increasing healthcare expenditure, further boosts the market for cancer immunotherapies in North America. With advancements in precision medicine and the integration of genomic data into treatment regimens, the region is expected to continue leading the market for cancer immunotherapy over the forecast period. Competitive Landscape and Leading Companies The cancer immunotherapy market is highly competitive, with several leading biopharmaceutical companies driving innovation and market growth. Companies such as Merck & Co., Bristol Myers Squibb, Roche, and Pfizer are at the forefront of developing and commercializing cancer immunotherapy drugs. These industry leaders have established extensive portfolios of immuno-oncology drugs, including checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, which are essential in the treatment of various cancers. In addition to these large players, numerous smaller biotechnology companies are also making significant strides in developing innovative therapies. These companies often collaborate with larger pharmaceutical firms to leverage their research capabilities and clinical trial infrastructure. The ongoing trend of mergers and acquisitions (M&A) in the industry further intensifies competition, as companies aim to expand their portfolios and strengthen their positions in the immuno-oncology market. The competitive landscape remains dynamic, with increasing investments in R&D, strategic partnerships, and a focus on overcoming the challenges of resistance and side effects associated with current therapies. Recent Developments: • Bristol Myers Squibb: Announced the approval of its new immunotherapy drug, Opdivo, for the treatment of non-small cell lung cancer in the U.S. market. • Merck & Co., Inc.: Merck has entered into a strategic partnership with a biotech company to co-develop a next-generation checkpoint inhibitor for cancer treatment. • Roche Holding AG: Received regulatory approval in Europe for Tecentriq, a PD-L1 inhibitor, for use in multiple types of cancer including bladder and lung cancers. • Johnson & Johnson: Launched an immuno-oncology combination therapy to treat metastatic prostate cancer, offering an alternative to chemotherapy. • AstraZeneca PLC: Announced an acquisition of a promising immuno-oncology start-up, strengthening its pipeline for lung cancer therapies List of Leading Companies: • Bristol Myers Squibb • Merck & Co., Inc. • Roche Holding AG • Johnson & Johnson • Novartis International AG • Pfizer, Inc. • Eli Lilly and Co. • AstraZeneca PLC • Sanofi S.A. • Amgen Inc. • Regeneron Pharmaceuticals, Inc. • Gilead Sciences, Inc. • AbbVie Inc. • Celgene Corporation • GlaxoSmithKline PLC Report Scope: Report Features Description Market Size (2023) USD 154.5 Billion Forecasted Value (2030) USD 338.3 Billion CAGR (2024 – 2030) 11.9% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Cancer Immunotherapy Market by Product Type (Monoclonal Antibodies, Checkpoint Inhibitors, Cytokine Therapies, Vaccines, CAR-T Cell Therapies), by Service Type (Preclinical Discovery, Clinical Trial Services, Discovery Services, Regulatory Consulting), by Therapeutic Area (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer), by End-User Industry (Biopharmaceutical Companies, Research & Development Institutes, Academic & Research Institutions, Contract Research Organizations (CROs)) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Bristol Myers Squibb, Merck & Co., Inc., Roche Holding AG, Johnson & Johnson, Novartis International AG, Pfizer, Inc., Eli Lilly and Co., AstraZeneca PLC, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., AbbVie Inc., Celgene Corporation, GlaxoSmithKline PLC Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements